Research Article

Correlation between methylation level of the SLC19A1 promoter region and methotrexate metabolism in adult acute lymphoblastic leukemia

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, 300020, China

Search for more papers by this author

Qishan Hao

Search for more papers by this author

Qiuyun Fang

Search for more papers by this author

Ping Zhang

Search for more papers by this author

Hui Wei

Search for more papers by this author

Ying Wang

Search for more papers by this author

Jianxiang Wang

Search for more papers by this author

Yingchang Mi

*Author for correspondence:

E-mail Address: ychmi@ihcams.ac.cn

Search for more papers by this author

Published Online:31 Mar 2023https://doi.org/10.2217/pgs-2022-0169

View article

Abstract

Aims: To analyze the methylation level in the promoter region of SLC19A1 in adult acute lymphoblastic leukemia (ALL) patients, and explore the relationship between methotrexate (MTX) drug metabolism and SLC19A1 methylation. Methods: The methylation levels of the SLC19A1 promoter region in 52 adult ALL patients who received high-dose MTX chemotherapy were retrospectively analyzed in combination with clinical indicators and plasma MTX concentration. Results: Methylation levels of 17 CpG units were differently correlated with clinical parameters of ALL patients including gender, age, immunophenotype and Philadelphia chromosome status. Patients with delayed MTX drug excretion had higher methylation levels in the SLC19A1 promoter region. Conclusion: The methylation may affect the MTX plasma level and adverse reactions, which may predict patients at risk of adverse reactions after high-dose MTX therapy.

Keywords:

References

1. Hematology Oncology Committee, Chinese Anti-Cancer Association, Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of acute lymphoblastic leukemia (2016). Zhonghua Xue Ye Xue Za Zhi 37(10), 837–845 (2016).
MedlineGoogle Scholar
2. Wang SM, Li M, Wu WS, Sun LL, Yan D. Methylation analysis of theSLC19A1 promoter region in Chinese children with acute lymphoblastic leukaemia. J. Clin. Pharm. Ther. 45(4), 646–651 (2020).
Medline CASGoogle Scholar
3. Bassan R, Bourquin JP, DeAngelo DJ, Chiaretti S. New approaches to the management of adult acute lymphoblastic leukemia. J. Clin. Oncol. 36(35), JCO2017773648 (2018).
Google Scholar
4. Kotur N, Lazic J, Ristivojevic B et al. Pharmacogenomic markers of methotrexate response in the consolidation phase of pediatric acute lymphoblastic leukemia treatment. Genes (Basel) 11(4), 468 (2020).
Medline CASGoogle Scholar
5. Matherly LH, Wilson MR, Hou Z. The major facilitative folate transporters solute carrier 19A1 and solute carrier 46A1: biology and role in antifolate chemotherapy of cancer. Drug Metab. Dispos. 42(4), 632–649 (2014).
MedlineGoogle Scholar
6. Cwiklinska M, Czogala M, Kwiecinska K et al. Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and tandem TS repeats influence pharmacokinetics, acute liver toxicity, and vomiting in children with acute lymphoblastic leukemia treated with high doses of methotrexate. Front. Pediatr. 8, 307 (2020).
MedlineGoogle Scholar
7. Ferreri AJ, Dell’Oro S, Capello D et al. Aberrant methylation in the promoter region of the reduced folate carrier gene is a potential mechanism of resistance to methotrexate in primary central nervous system lymphomas. Br. J. Haematol. 126(5), 657–664 (2004).
Medline CASGoogle Scholar
8. He PF, Xu ZJ, Zhou JD et al. Methylation-associated DOK1 and DOK2 down-regulation: potential biomarkers for predicting adverse prognosis in acute myeloid leukemia. J. Cell. Physiol. 233(9), 6604–6614 (2018).
Medline CASGoogle Scholar
9. Luskin MR, Gimotty PA, Smith C et al. A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. JCI Insight 1(9), e87323 (2016).
MedlineGoogle Scholar
10. Zhou F, Chen B. Prognostic significance of ferroptosis-related genes and their methylation in AML. Hematology 26(1), 919–930 (2021).
Medline CASGoogle Scholar
11. von Kanel T, Huber AR. DNA methylation analysis. Swiss Med. Wkly 143, w13799 (2013).
Medline CASGoogle Scholar
12. Mackowska N, Drobna-Sledzinska M, Witt M, Dawidowska M. DNA methylation in T-cell acute lymphoblastic leukemia: in search for clinical and biological meaning. Int. J. Mol. Sci. 22(3), 1388 (2021).
Medline CASGoogle Scholar
13. Angeloni A, Bogdanovic O. Enhancer DNA methylation: implications for gene regulation. Essays Biochem. 63(6), 707–715 (2019).
Medline CASGoogle Scholar
14. Watanabe A, Miyake K, Nordlund J et al. Association of aberrant ASNS imprinting with asparaginase sensitivity and chromosomal abnormality in childhood BCP-ALL. Blood 136(20), 2319–2333 (2020).
Medline CASGoogle Scholar
15. Akahane K, Kimura S, Miyake K et al. Association of allele-specific methylation of the ASNS gene with asparaginase sensitivity and prognosis in T-ALL. Blood Adv. 6(1), 212–224 (2022).
Medline CASGoogle Scholar
16. Roolf C, Richter A, Konkolefski C et al. Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements. J. Hematol. Oncol. 11(1), 62 (2018).
Medline CASGoogle Scholar
17. Svaton M, Skvarova KK, Kanderova V et al. A homozygous deletion in the SLC19A1 gene as a cause of folate-dependent recurrent megaloblastic anemia. Blood 135(26), 2427–2431 (2020).
MedlineGoogle Scholar
18. Lima A, Bernardes M, Sousa H et al. SLC19A1 80G allele as a biomarker of methotrexate-related gastrointestinal toxicity in Portuguese rheumatoid arthritis patients. Pharmacogenomics 15(6), 807–820 (2014).
CASGoogle Scholar
19. Mahmuda NA, Yokoyama S, Huang JJ et al. A study of single nucleotide polymorphisms of the SLC19A1/RFC1 gene in subjects with autism spectrum disorder. Int. J. Mol. Sci. 17(5), 772 (2016).
MedlineGoogle Scholar
20. Mohtaram S, Sheikhha MH, Honarvar N et al. An association study of the SLC19A1 gene polymorphisms/haplotypes with idiopathic recurrent pregnancy loss in an Iranian population. Genet. Test. Mol. Biomarkers 20(5), 235–240 (2016).
Medline CASGoogle Scholar
21. Zhou J, Xiong Y, Dong X et al. Genome-wide methylation analysis reveals differentially methylated CpG sites and altered expression of heart development-associated genes in fetuses with cardiac defects. Exp. Ther. Med. 22(3), 1032 (2021).
Medline CASGoogle Scholar
22. Li C, Yuan B, Yu X et al. SLC19A1 may serve as a potential biomarker for diagnosis and prognosis in osteosarcoma. Clin. Lab. 66(11). doi:10.7754/Clin.Lab.2020.200246 (2020).
Google Scholar
23. Gosselt HR, van Zelst BD, de Rotte M et al. Higher baseline global leukocyte DNA methylation is associated with MTX non-response in early RA patients. Arthritis Res. Ther. 21(1), 157 (2019).
MedlineGoogle Scholar
24. Ma D, Huang H, Moscow JA. Down-regulation of reduced folate carrier gene (RFC1) expression after exposure to methotrexate in ZR-75-1 breast cancer cells. Biochem. Biophys. Res. Commun. 279(3), 891–897 (2000).
Medline CASGoogle Scholar
25. Imamura H, Yoshina S, Ikari K et al. Impaired NFKBIE gene function decreases cellular uptake of methotrexate by down-regulating SLC19A1 expression in a human rheumatoid arthritis cell line. Mod. Rheumatol. 26(4), 507–516 (2016).
Medline CASGoogle Scholar
26. Moscow JA, Gong M, He R et al. Isolation of a gene encoding a human reduced folate carrier (RFC1) and analysis of its expression in transport-deficient, methotrexate-resistant human breast cancer cells. Cancer Res. 55(17), 3790–3794 (1995).
Medline CASGoogle Scholar

Vol. 24, No. 5

Supplemental Materials

Metrics

Downloaded 123 times

History

Received 18 November 2022

Accepted 28 February 2023

Published online 31 March 2023

Published in print April 2023

Information

Keywords

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at: www.futuremedicine.com/doi/suppl/10.2217/pgs-2022-0169

Acknowledgments

The authors thank the patients for their participation, and colleagues in the Clinical Pharmacy Department for their work.

Financial & competing interests disclosure

This work was supported by Science and Technology Project of Tianjin (no. 21JCQNJC01540), National Science and Technology Major Project (no. 2017ZX09304024). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Ethical conduct of research

This study was approved by the Ethics Committee of the Institute of Hematology & Blood Disease Hospital of the Chinese Academy of Medical Sciences (ethical approval serial no. KT2015001-EC-1). Informed consent was signed by all enrolled patients or their guardians.

PDF download